Drug resistance, developed through multiple mechanisms, is a major hindrance to
successful chemotherapy of tumor. Combination therapy of chemotherapeutic drugs and …

DNA damaging chemotherapy is the first line of treatment for certain cancers, but its
longterm success is often marred by the eventual acquisition of chemoresistance. Other …

Abstracts Cell-penetrating peptides (CPPs), also known as protein transduction domains,
are a class of diverse amino acid sequences with the ability to cross cellular membranes …

Cancer prognosis remains a lottery dependent on cancer type, disease stage at diagnosis,
and personal genetics. While investment in research is at an all‐time high, new drugs are …

Tumor heterogeneity is the major cause of failure in cancer prognosis and prediction.
Accurately detecting heterogeneity for the development of biomarkers and the detection of …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized
by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic …

Lysosomal sequestration of anti-cancer compounds reduces drug availability at intracellular
target sites, thereby limiting drug-sensitivity and inducing chemoresistance. For …

In the recent past, proteolysis-targeting chimera (PROTAC) technology has received
enormous attention for its ability to overcome the limitations of protein inhibitors and its …

Abstract Acyl-CoA synthetase-4 (ACSL4) is an enzyme implicated in estrogen receptor α
(ERα) negative regulation and hormone therapy resistance in breast cancer. In addition …

Chemotherapy is one of the main methods for cancer treatment. However, despite many
advances in the design of anticancer drugs, their efficiency is limited due to their high toxicity …